Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at UCLA Health

Sites in Los Angeles, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1099
Shown on this page
12
Current sort
Recently updated
Campus scope
UCLA Health, Los Angeles, CA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within UCLA Health, Los Angeles, CA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 349–360 of 1,099 matching trials with a site at UCLA Health, Los Angeles, CA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 2 Interventional

Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)

NCT05186974
Site status not listed — check the official record
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Sacituzumab Govitecan-hziy (SG), Pembrolizumab, Carboplatin, Cisplatin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
22
States / cities
Anchorage, Alaska • Beverly Hills, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 23, 2026, 9:05 PM EDT
Recruiting Not applicable Interventional

Extracorporeal Shockwave Therapy (ESWT) for the Management of Stress Fractures and High-grade Bone Stress Injuries (BSIs)

NCT06609265
Status at this site: Recruiting
View directory record Official record
Conditions
Bones Stress Injury, Bone Stress Fracture
Interventions
Extracorporeal shockwave treatment (ESWT)., Sham Device
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 50 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Los Angeles, California • Redwood City, California • Cambridge, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 23, 2026, 9:05 PM EDT
Recruiting Not applicable Interventional

I-DECIDE After Bronchiolitis Hospitalization

NCT07243652
Status at this site: Recruiting
View directory record Official record
Conditions
Bronchiolitis Acute
Interventions
Moderate-Resource Implementation Strategy, High-Resource Implementation Strategy
Other
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
0 Months to 24 Months
Enrollment
2,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
60
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 23, 2026, 9:05 PM EDT
Recruiting No phase listed Observational

Impact of Sinus Surgery on Individuals With Cystic Fibrosis

NCT04469439
Status at this site: Recruiting
View directory record Official record
Conditions
Chronic Rhinosinusitis (Diagnosis), Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 99 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Stanford, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 23, 2026, 9:05 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Safety and Efficacy Study of GEB-101 Injection in Subjects With TGFBI-related Corneal Dystrophy

NCT07750678
Site status not listed — check the official record
View directory record Official record
Conditions
Hereditary Corneal Dystrophy, Corneal Abnormality, Corneal Dystrophies, Corneal Dystrophies, Hereditary
Interventions
GEB-101 Injection
Genetic
Lead sponsor
GenEditBio Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 23, 2026, 9:05 PM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

NCT07453888
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Non-Arteritic Anterior Ischemic Optic Neuropathy
Interventions
Cenegermin, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
50 Years to 80 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
22
States / cities
Los Angeles, California • Newport Beach, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 23, 2026, 9:05 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

NCT06914128
Status at this site: Not yet recruiting
View directory record Official record
Conditions
MTAP-deleted Solid Tumors
Interventions
BAY 3713372
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
17
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 23, 2026, 9:05 PM EDT
Recruiting Phase 3 Interventional

Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia

NCT07184619
Status at this site: Suspended
View directory record Official record
Conditions
Treatment-resistant Schizophrenia
Interventions
Evenamide 15 mg bid, Placebo
Drug
Lead sponsor
Newron Pharmaceuticals SPA
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Miami, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 23, 2026, 9:05 PM EDT
Active, not recruiting Phase 3 Interventional

Long-term Extension of GTX-102 in Angelman Syndrome

NCT06415344
Site status not listed — check the official record
View directory record Official record
Conditions
Angelman Syndrome
Interventions
GTX-102
Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
Not listed
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
6
States / cities
Los Angeles, California • San Diego, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 23, 2026, 9:05 PM EDT
Active, not recruiting Phase 1 Interventional

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

NCT04227847
Site status not listed — check the official record
View directory record Official record
Conditions
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Interventions
SEA-CD70, azacitidine, Venetoclax
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
47
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 23, 2026, 9:05 PM EDT
Active, not recruiting No phase listed Observational

Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease

NCT06747572
Site status not listed — check the official record
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
Not listed
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years to 65 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
27
States / cities
Alabaster, Alabama • Birmingham, Alabama • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 23, 2026, 9:05 PM EDT
Recruiting Phase 1 Interventional

Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma

NCT06934889
Status at this site: Recruiting
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
ERAS-801, ABBV-637, ABBV-155, Temozolomide, Radiotherapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
11
States / cities
Los Angeles, California • Miami, Florida • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 23, 2026, 9:05 PM EDT

About this UCLA Health institution page

What this page lists
ClinicalTrials.gov records that list UCLA Health in Los Angeles, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.